PARP1 and cancer: However, we doubt whether this may be sufficient to counteract an increased activity of NAD+-degrading enzymes, for instance poly (ADP-ribose) polymerase 1 (PARP1) and CD38, due to inflammatory conditions induced by cancer cell metabolism itself as well as by treatment [55,56,57].